Announcements Trials
Browse Landscape

Phase

Phase 2 326Phase 1/2 103Phase 1 98Phase 3 52Phase NA 10Phase 4 9Phase EARLY_PHASE1 7Phase 2/3 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Lenalidomide × Clear all
NCT03759093 2023-09-06

CURATE.AI Optimized Modulation for Multiple Myeloma

National University Hospital, Singapore

Phase 2/3 Unknown
20 enrolled
Plasma cell

Multiple Myeloma

NCT02145598 2019-01-16

GERMAIN

University of Jena

Phase 2/3 Terminated
85 enrolled
Plasma cell

Multiple Myeloma

NCT02419118 2017-11-07

DARA

Vejle Hospital

Phase 2/3 Completed
4 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡